Recommended configuration for personal health records by standardized data item sets for diabetes mellitus and associated chronic diseases: a report from a collaborative initiative by six Japanese associations.

Autor: Nakashima N; 1Medical Information Center, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan., Noda M; 2Saitama Medical University, Saitama, Japan., Ueki K; 3National Center for Global Health and Medicine, Tokyo, Japan., Koga T; Hara Doi Hospital, Fukuoka, Japan., Hayashi M; 5NTT Medical Center Tokyo, Tokyo, Japan., Yamazaki K; Tsukuba Diabetic Center Kawai Clinic, Ibaraki, Japan., Nakagami T; 7Tokyo Women's Medical University, Tokyo, Japan., Ohara M; 8University of Tsukuba, Ibaraki, Japan., Gochi A; Ibara City Hospital, Okayama, Japan., Matsumura Y; 10Osaka University, Osaka, Japan., Kimura M; 11Hamamatsu University School of Medicine, Shizuoka, Japan., Ohe K; 12University of Tokyo, Tokyo, Japan., Kang D; 1Medical Information Center, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan., Toya Y; 13Yokohama City University, Kanagawa, Japan., Yamagata K; 8University of Tsukuba, Ibaraki, Japan., Yokote K; 14Chiba University, Chiba, Japan., Ikeda S; 15International University of Health and Welfare, Chiba, Japan., Mitsutake N; 16Institute for Health Economics and Policy, Tokyo, Japan., Yamamoto R; Medical Information System Development Center, Tokyo, Japan., Tanizawa Y; 18Yamaguchi University, Yamaguchi, Japan.
Jazyk: angličtina
Zdroj: Diabetology international [Diabetol Int] 2019 Apr 25; Vol. 10 (2), pp. 85-92. Date of Electronic Publication: 2019 Apr 25 (Print Publication: 2019).
DOI: 10.1007/s13340-019-00389-7
Abstrakt: It is expected that a large amount of data related to diabetes and other chronic diseases will be generated. However, databases constructed without standardized data item sets can be limited in their usefulness. To address this, the Collaborative Committee of Clinical Informatization in Diabetes Mellitus was established in 2011 by the Japan Diabetes Society and Japan Association for Medical Informatics. The committee has developed core item sets and self-management item sets for diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease in collaboration with the Japanese Society of Hypertension, Japan Atherosclerosis Society, Japanese Society of Nephrology, and Japanese Society of Laboratory Medicine, as well as a mapping table that aligns the self-management item sets with the Japanese standardized codes for laboratory testing. The committee also determined detailed specifications for implementing the four self-management item sets in personal health record applications to facilitate risk stratification, the generation of alerts using information and communications technology systems, the avoidance of data input errors, and the generation of reminders to input the self-management item set data. The approach developed by the committee may be useful for combining databases for various purposes (such as for clinical studies, patient education, and electronic medical record systems) and for facilitating collaboration between personal health record administrators.
Competing Interests: Naoki Nakashima has received research grants from Fujitsu Ltd. Kohjiro Ueki has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca Co., Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Co. Ltd., MSD Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd, Sanofi Aventis Co. Ltd, Shionogi & Co. Ltd., Sumitomo Dainippon Co. Ltd, Taisho Toyama Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co Ltd., and research grants from Astellas Pharma Inc. He has also received scholarship grants from Astellas Pharma Inc, Daiichi Sankyo Co. Ltd., Eli Lilly Japan Co. Ltd., Kowa Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., Sanofi Aventis Co. Ltd., Sumitomo Dainippon Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co Ltd. Koutaro Yokote has received honoraria for lectures from Astellas Pharma Inc., Astellas Amgen BioPharma Co. Ltd., AstraZeneca Co., Ltd., MSD Co. Ltd., Ono Pharmaceutical Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Kowa Co. Ltd., Kowa Pharmaceutical Co., Ltd, Sanofi Aventis Co. Ltd., Shionogi & Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co Ltd., Mitsubishi Tanabe Co. Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Co. Ltd., Eli Lilly Japan Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., and Mochida Pharmaceutical Co. Ltd., and research grants from Astellas Pharma Inc. He has also received scholarship grants from Astellas Pharma Inc., MSD Co. Ltd., Ono Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Co. Ltd., Teijin Pharm Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Co. Ltd., Eli Lilly Japan Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., and Mochida Pharmaceutical Co. Ltd., and a course endowed by MSD Co. Ltd. Mitsuhiko Noda, Tatsuhiko Koga, Michio Hayashi, Katsuya Yamazaki, Tomoko Nakagami, Makoto Ohara, Akira Gochi, Yasushi Matsumura, Michio Kimura, Kazuhiko Ohe, Dongchon Kang, Yoshiyuki Toya, Kunihiro Yamagata, Shunya Ikeda, Naohiro Mitsutake, Ryuichi Yamamoto, and Yukio Tanizawa have no conflict of interest.There are no ethical issues associated with this report.
Databáze: MEDLINE
Externí odkaz: